文献速递前列腺癌

根治性前列腺切除或放疗后生化复发患者无种族特异性死亡率差异

No racial disparities in prostate cancer-specific mortality after biochemical recurrence following radical prostatectomy or radiation therapy.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2026-07-10

该回顾性单中心研究纳入1995至2023年间根治性前列腺切除或放疗后出现生化复发的968例患者(非西班牙裔黑人431例,非西班牙裔白人537例),中位随访5.5年。结果显示两组前列腺癌特异性死亡率及其他原因死亡率均无显著差异,支持种族差异反映可改变的医疗可及性障碍而非生物学差异。

要点

  • 生化复发后十年癌症特异性死亡率在根治性前列腺切除组两族均为6.7%。
  • 放疗组十年癌症特异性死亡率非西班牙裔黑人为26.7%,非西班牙裔白人为32.4%。
  • 其他原因死亡率两组相似,支持差异源于医疗可及性而非生物学。

核心结论

  • 在 racially diverse 单中心队列中,生化复发后癌症特异性死亡率和其他原因死亡率均无种族差异。

研究设计与样本

  • 回顾性单健康系统研究,纳入1995至2023年间根治性前列腺切除或放疗后出现生化复发的患者,共968例(非西班牙裔黑人431例,44.5%;非西班牙裔白人537例,55.5%)。
  • 采用Fine-Gray竞争风险模型评估种族与癌症特异性死亡率的关联,按治疗分层并依据欧洲泌尿外科学会生化复发风险分类进行调整。

主要发现

  • 中位随访时间自生化复发起为5.5年。
  • 其他原因死亡率两组相似(Gray's检验:根治性前列腺切除p=0.35,放疗p=0.41)。
  • 根治性前列腺切除后十年癌症特异性死亡率两族均为6.7%(非西班牙裔黑人 vs 非西班牙裔白人 HR 0.91,95%CI 0.49-1.71,p=0.8)。
  • 放疗后十年癌症特异性死亡率非西班牙裔黑人为26.7%,非西班牙裔白人为32.4%(HR 0.71,95%CI 0.44-1.14,p=0.16)。

临床怎么用

  • 对于根治性前列腺切除或放疗后生化复发的患者,应提供公平的后续治疗和监测,不应基于种族差异调整治疗策略。
  • 研究结果支持将种族差异归因于可改变的医疗可及性障碍,强调公平医疗交付的重要性。

局限性

  • 单中心设计。
  • 回顾性研究方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Racial disparities in prostate cancer are well-documented, with Black men experiencing twice the mortality of White men. While prior studies suggest these disparities reflect inequitable access rather than biology, only few studies have examined this in the biochemical recurrence setting, where screening and initial treatment biases are eliminated. We compared cancer-specific mortality and other-cause mortality between non-Hispanic Black (NHB) and non-Hispanic White (NHW) men with biochemical recurrence after initial treatment. METHODS: This retrospective single health system study included patients who developed BCR after radical prostatectomy or radiation therapy between 1995 and 2023. Primary outcome was cancer-specific mortality. Fine-Gray competing risk models assessed race-CSM association, stratified by treatment and adjusted for European Association of Urology biochemical recurrence risk classification. RESULTS: Among 968 patients (431 NHB, 44.5%; 537 NHW, 55.5%), median follow-up was 5.5 years from biochemical recurrence. Other-cause mortality was similar (Gray's test p = 0.35 radical prostatectomy, p = 0.41 radiation therapy). Ten-year cancer-specific mortality estimates were similar after radical prostatectomy (6.7% both races; NHB versus NHW HR 0.91, 95% CI 0.49-1.71, p = 0.8) and radiation therapy (NHB 26.7% versus NHW 32.4%; HR 0.71, 95% CI 0.44-1.14, p = 0.16). Limitations include single-center design and retrospective methodology. CONCLUSIONS: In this racially diverse single-center cohort, we found no racial disparities in cancer-specific mortality or other-cause mortality after biochemical recurrence. These findings support that racial disparities reflect modifiable access barriers rather than biological differences, emphasizing the importance of equitable care delivery.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Silvani C, Santangelo A, Stephens A, et al. No racial disparities in prostate cancer-specific mortality after biochemical recurrence following radical prostatectomy or radiation therapy. Prostate Cancer Prostatic Dis. 2026. PMID: 42432266. doi:10.1038/s41391-026-01132-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。